

# Francesco Di Mario

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6314566/publications.pdf>

Version: 2024-02-01

59  
papers

1,806  
citations

304368

22  
h-index

276539

41  
g-index

59  
all docs

59  
docs citations

59  
times ranked

1867  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gastric Cancer as Preventable Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1833-1843.	2.4	162
2	Proton pump inhibitors in GORDAn overview of their pharmacology, efficacy and safety. <i>Pharmacological Research</i> , 2009, 59, 135-153.	3.1	156
3	Diverticular Disease in the Elderly. <i>Digestive Diseases</i> , 2007, 25, 151-159.	0.8	125
4	A Curcumin-Based 1-Week Triple Therapy for Eradication of <i>Helicobacter pylori</i> Infection: Something to Learn From Failure?. <i>Helicobacter</i> , 2007, 12, 238-243.	1.6	111
5	Guidelines for the management of <i>Helicobacter pylori</i> infection in Italy: The III Working Group Consensus Report 2015. <i>Digestive and Liver Disease</i> , 2015, 47, 903-912.	0.4	106
6	Efficacy of Mesalazine in the Treatment of Symptomatic Diverticular Disease. <i>Digestive Diseases and Sciences</i> , 2005, 50, 581-586.	1.1	102
7	Prevention of Complications and Symptomatic Recurrences in Diverticular Disease with Mesalazine: A 12-Month Follow-up. <i>Digestive Diseases and Sciences</i> , 2007, 52, 2934-2941.	1.1	74
8	Quality of Life in Uncomplicated Symptomatic Diverticular Disease: Is It Another Good Reason for Treatment?. <i>Digestive Diseases</i> , 2007, 25, 252-259.	0.8	72
9	Chronicles of a cancer foretold: 35 years of gastric cancer risk assessment. <i>Gut</i> , 2016, 65, 721-725.	6.1	72
10	Mesalazine for the Treatment of Symptomatic Uncomplicated Diverticular Disease of the Colon and for Primary Prevention of Diverticulitis. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, S64-S69.	1.1	52
11	Usefulness of Serum Pepsinogens in <i>Helicobacter pylori</i> Chronic Gastritis: Relationship With Inflammation, Activity, and Density of the Bacterium. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1791-1795.	1.1	50
12	Rescue™ Therapies for the Management of <i>Helicobacter pylori</i> Infection. <i>Digestive Diseases</i> , 2006, 24, 113-130.	0.8	49
13	Prevention of acute NSAID-related gastroduodenal damage: a meta-analysis of controlled clinical trials. <i>Digestive Diseases and Sciences</i> , 2001, 46, 1924-1936.	1.1	39
14	Efficacy of 5-ASA in the Treatment of Colonic Diverticular Disease. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 113-119.	1.1	39
15	Use of Lactoferrin for <i>Helicobacter pylori</i> Eradication. <i>Journal of Clinical Gastroenterology</i> , 2003, 36, 396-398.	1.1	35
16	New bismuth-containing quadruple therapy in patients infected with <i>Helicobacter pylori</i> : A first Italian experience in clinical practice. <i>Helicobacter</i> , 2017, 22, e12371.	1.6	34
17	Predictive value of the Diverticular Inflammation and Complication Assessment (DICA) endoscopic classification on the outcome of diverticular disease of the colon: An international study. <i>United European Gastroenterology Journal</i> , 2016, 4, 604-613.	1.6	33
18	Gastric acid secretion: Changes during a century. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 953-965.	1.0	32

#	ARTICLE	IF	CITATIONS
19	Use of Mesalazine in Diverticular Disease. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, S155-S159.	1.1	30
20	Diverticular Disease: a Gut Microbiota Perspective. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 327-337.	0.5	30
21	Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels. <i>Fundamental and Clinical Pharmacology</i> , 2005, 19, 497-501.	1.0	28
22	The Clinical Usefulness of Serum Pepsinogens, Specific IgG Anti- <i>HP</i> Antibodies and Gastrin for Monitoring <i>Helicobacter pylori</i> Treatment in Older People. <i>Journal of the American Geriatrics Society</i> , 1996, 44, 665-670.	1.3	24
23	Quantification of Serum Levels of Pepsinogens and Gastrin to Assess Eradication of <i>Helicobacter Pylori</i> . <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 440-442.	2.4	23
24	Is There a Role for Probiotics in <i>Helicobacter pylori</i> Therapy?. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 565-575.	1.0	22
25	Effectiveness and Safety of Pylera® in Patients Infected by <i>Helicobacter Pylori</i> : A Multicenter, Retrospective, Real Life Study. <i>Digestive Diseases</i> , 2018, 36, 264-268.	0.8	22
26	Clinical Usefulness of Serum Pepsinogen II in the Management of <i>Helicobacter pylori</i> Infection. <i>Digestion</i> , 2004, 70, 167-172.	1.2	21
27	International Consensus on Diverticulosis and Diverticular Disease. Statements from the 3rd International Symposium on Diverticular Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 57-66.	0.5	21
28	Gastric Juice Polymerase Chain Reaction: An Alternative to Histology in the Diagnosis of <i>Helicobacter pylori</i> Infection. <i>Helicobacter</i> , 1996, 1, 159-164.	1.6	20
29	Long-term efficacy of rifaximin to manage the symptomatic uncomplicated diverticular disease of the colon. <i>Journal of Investigative Medicine</i> , 2019, 67, 767-770.	0.7	19
30	Recurrent Diverticulitis. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 1130-1134.	1.1	18
31	Long-term treatment with mesalazine in patients with symptomatic uncomplicated diverticular disease. <i>Internal and Emergency Medicine</i> , 2012, 7, 133-137.	1.0	18
32	Natural Course of Functional Dyspepsia After <i>Helicobacter pylori</i> Eradication: A Seven-Year Survey. <i>Digestive Diseases and Sciences</i> , 2005, 50, 2286-2295.	1.1	16
33	Pepsinogen II in gastritis and <i>Helicobacter pylori</i> infection. <i>Helicobacter</i> , 2022, 27, e12872.	1.6	13
34	Relationship between <i>Helicobacter pylori</i> infection and GERD. <i>Acta Biomedica</i> , 2018, 89, 40-43.	0.2	12
35	Burning Mouth Syndrome Etiology: A Narrative Review. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2022, 31, 223-228.	0.5	11
36	Serum pepsinogen C: A useful marker of <i>Helicobacter pylori</i> eradication?. , 1996, 10, 1-5.		10

#	ARTICLE	IF	CITATIONS
37	Risk factors for endoscopic severity of diverticular disease of the colon and its outcome: a real-life case-control study. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1123-1129.	0.8	10
38	The natural history of symptomatic uncomplicated diverticular disease: a long-term follow-up study. <i>Annals of Gastroenterology</i> , 2020, 34, 208-213.	0.4	10
39	The prevalence of symptomatic uncomplicated diverticular disease could be lower than expected: a single-center colonoscopy-based cohort study. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e478-e483.	0.8	9
40	Rabeprazole in a one-week eradication therapy of <i>Helicobacter pylori</i> : Comparison of different dosages. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 783-786.	1.4	8
41	Non-invasive method for the assessment of gastric acid secretion. <i>Acta Biomedica</i> , 2018, 89, 53-57.	0.2	7
42	Recovery of gastric function after <i>Helicobacter pylori</i> eradication in subjects with body atrophic gastritis: Prospective 4-year study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 1661-1666.	1.4	6
43	The Sleeping Remnant. Effect of Roux-En-Y Gastric Bypass on Plasma Levels of Gastric Biomarkers in Morbidly Obese Women: A Prospective Longitudinal Study. <i>Obesity Surgery</i> , 2017, 27, 1901-1905.	1.1	6
44	Rifaximin for the Management of Colonic Diverticular Disease: far Beyond a Simple Antibiotic. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2018, 27, 351-355.	0.5	6
45	The "DICA" Endoscopic Classification for Diverticular Disease of the Colon Shows a Significant Interobserver Agreement among Community Endoscopists. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 23-27.	0.5	6
46	Impact of diverticular inflammation and complication assessment classification on the burden of medical therapies in preventing diverticular disease complications in Italy. <i>Annals of Translational Medicine</i> , 2017, 5, 320-320.	0.7	5
47	Efficacy and safety of a new nutraceutical formulation in managing patients with symptomatic uncomplicated diverticular disease: a 12-month, prospective, pilot study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 27, 201-203.	0.5	5
48	What's New in Diagnosing Diverticular Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 17-22.	0.5	5
49	Serum levels of vitamin D are associated with the severity of the endoscopic appearance of diverticular disease of the colon according to DICA classification. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2016, 25, 567-568.	0.5	4
50	A Primary-Care Interventional Model on the Diverticular Disease. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, S93-S96.	1.1	3
51	Low Levels of Gastrin 17 are Related with Endoscopic Findings of Esophagitis and Typical Symptoms of GERD. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2021, 30, 25-29.	0.5	3
52	Personality Patterns and Duodenal Ulcer Relapse under Antisecretory Treatment*. <i>Canadian Journal of Psychiatry</i> , 1987, 32, 777-778.	0.9	2
53	Advances in GI Pharmacology and Therapeutics. <i>Digestive Diseases</i> , 2006, 24, 7-10.	0.8	2
54	The DICA Endoscopic Classification for Diverticular Disease of the Colon Shows a Significant Interobserver Agreement among Community Endoscopists: an International Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 39-44.	0.5	2

#	ARTICLE	IF	CITATIONS
55	Functional Dyspesia. Acta Biomedica, 2020, 91, e2020069.	0.2	2
56	Abnormal Levels of Pepsinogen I and Gastrin 17 in a case of MÃ©nÃ©trier Disease. Acta Biomedica, 2021, 92, e2021207.	0.2	2
57	Misleading results in the diagnosis of atrophic gastritis. European Journal of Gastroenterology and Hepatology, 2014, 26, 1439-1440.	0.8	1
58	Barrett's esophagus: results from an Italian cohort with tight endoscopic surveillance.. Acta Biomedica, 2022, 93, e2022130.	0.2	1
59	Low levels of G17 and Barrett esophagus: a clinical relationship. Clinical Chemistry and Laboratory Medicine, 2022, .	1.4	0